Medtronic's Former VP Chris Cleary Joins Restore Medical in Heart Failure Innovation
- Chris Cleary, former Medtronic executive, joins Restore Medical as Chairman to lead heart failure therapy development.
- Cleary's experience includes overseeing Medtronic's $50 billion acquisition of Covidien, enhancing his strategic impact.
- Restore Medical aims to innovate heart failure treatments, addressing significant patient needs and improving healthcare outcomes.
Innovative Leadership in Heart Failure Treatment Development
Restore Medical Ltd., an emerging player in the medical device sector, is making significant strides in its clinical pathway for a groundbreaking transcatheter therapy aimed at treating heart failure with reduced ejection fraction (HFrEF). The company, based in Or-Yehuda, Israel, announces the strategic appointment of Chris Cleary as Chairman of its Board of Directors. Cleary, who previously served as the Senior Vice President of Corporate Development at Medtronic, brings over three decades of experience in healthcare and medical technology to the role. His background includes overseeing transformative transactions that have reshaped the healthcare landscape, such as Medtronic’s substantial $50 billion acquisition of Covidien.
Under Cleary's leadership, Restore Medical aims to bolster its clinical development efforts and expand its global reach. The company prepares for pivotal studies of its innovative therapy, which it believes can significantly improve the quality of life for millions suffering from heart failure. Gilad Marom, the CEO of Restore Medical, expresses confidence in Cleary’s strategic insight and commitment to driving medical innovation. He emphasizes the urgency of addressing the unmet needs within heart failure treatment, highlighting the potential impact of Restore Medical’s offerings in a market that demands effective and minimally invasive solutions.
The company garners support from notable healthcare investors, including Pitango HealthTech and Peregrine Ventures, along with backing from the European Innovation Council (EIC) Fund. This robust financial support positions Restore Medical to navigate the critical phases of clinical trials and commercialization. Cleary’s appointment signals a pivotal moment for the company as it lays the groundwork for its innovative therapy, aiming to transform treatment options for heart failure patients globally. As Restore Medical advances, it remains focused on its mission to enhance patient outcomes through groundbreaking technology.
In related news, Restore Medical’s innovative approach aligns with a growing trend in the medical device industry towards minimally invasive therapies. With heart failure being a leading cause of morbidity and mortality worldwide, companies like Restore Medical are crucial in developing solutions that address this pressing healthcare challenge. The medical community watches closely as Restore Medical moves forward with its promising therapy, potentially setting new standards in heart failure management.
Related Cashu News

Merit Medical Systems Launches Employee Stock Ownership Plan to Boost Engagement and Stability
Merit Medical Systems (Ticker: MMSI) recently takes a significant step in enhancing its employee engagement and ownership structure with the launch of a new Employee Stock Ownership Plan (ESOP). The c…

Brookdale Senior Living launches second season of educational podcast "The Grey Take.
Brookdale Senior Living (Ticker: BKD) launches the second season of its popular podcast, "The Grey Take," which serves as a valuable resource for families exploring senior living options. The podcast…

Molina Healthcare Gains Momentum with Increased Risk Adjustment Payments and Positive Revenue Outlook
Molina Healthcare (Ticker: MOH) is making significant strides in its revenue outlook due to recently released risk adjustment figures from the Centers for Medicare & Medicaid Services (CMS). These upd…

Align Technology Faces Antitrust Investigation by European Commission Over Competitive Practices
Align Technology Inc. (Ticker: ALGN) faces a formal antitrust investigation from the European Commission, marking a significant development in the medical devices sector. This inquiry arises from a co…

